Israeli digital therapeutics company Theranica, a developer of the Nerivio migraine-zapping treatment, announced that the device would now be available in Israel, following an initial launch in the US.
The device is worn on the upper arm and provides migraine treatment through neuromodulation therapy, altering nerve activity through targeted delivery of a stimulus. The treatment is like “a personalized pain-relief program,” according to the Netanya-based company. It is controlled via app and offers a migraine diary to track treatment sessions and migraine headaches which can be shared with healthcare professionals.
The unit is good for 12 treatments, after which it can be recycled, and the prescription refilled with a new device.
The FDA-cleared was approved for use in adolescents in January, contributing to the company’s growth trajectory. In an announcement on Tuesday, Theranica said it has seen consistent growth in the usage of Nerivio, marking more than 100,000 treatments in the US.
The milestone, the company said in a statement, follows a recent study published in Headache, the official peer-reviewed journal of the American Headache Society, that evaluated the efficacy of Nerivio in episodic and chronic migraine patients between the ages of 12 and 17. At two hours post treatment, 71 percent of participants reported pain relief and 35 percent reported pain freedom. Pain relief and pain freedom were sustained for 24 hours in 90 percent of the cases.
“We are at a crossroads for acute migraine treatment, where traditional drug-based solutions are being challenged by FDA-authorized, novel digital therapeutics such as Nerivio,” said Ronen Jashek, co-founder and COO of Theranica. “We are pleased to see that Nerivio patients are showing both adherence to the treatment program and an increased level of comfort with the device itself. 100,000 treatments hold significance to Theranica, as does our recent 33 percent growth in monthly active users, because these numbers demonstrate that Nerivio users consistently see the benefits of this prescribed therapy to their well-being.”
Nerivio was featured on Time Magazine’s list of 100 Best Innovations in 2019, alongside eight other Israeli innovations, and as a “game-changing” medical tech company in 2020 by New York-based research firm CB Insights.